July 31, 2014
According to an article published in PLoSOne, researchers from IDIBAPS reconstitute a new nasal respiratory epithelium from mature stem cells of the nasal mucosa of both healthy and inflamed tissue. They have met their objectives by using a technique based in the exposure of primary culture cells to the air.
July 25, 2014
Euroimmun acquires the rights of a patent developed by Dr. Graus and Dr. Dalmau for the diagnosis of autoimmune diseases
Dr. Graus and Dr. Dalmau have developed a technology for the diagnosis, prognosis and treatment of patients with an autoimmune disease associated to sleep disorders. It is based on detecting the presence of antibodies against the neuronal protein IGLON5 by immunocytochemistry of transfected cells.
July 18, 2014
The report named "Spanish Participation in the Innovative Medicines Initiative (IMI)" has been recently published by the Center for Industrial Technological Development (CDTI). This report lists the main indicators of participation in 8 of the 11 IMI’s calls supported under the 7th Framework Programme.
July 8, 2014
In the context of the Graphene Week 2014, the European Commission announced that the Graphene Flagship, one of the largest European research initiatives, is doubling its size and now includes more than 140 organizations from 23 countries. IDIBAPS is one of new 66 partners of the consortium through the team of Maria Victoria Sánchez-Vives, MD, PhD, ICREA Research Professor and team leader of the IDIBAPS group Systems Neuroscience. Professor Sanchez-Vives joins the Neurographene project, coordinated by Rosa Villa, PhD, from the CIBER-BBN Biomonitoring Group at the Barcelona Microelectronics Institute (IMB-CNM), and whose aim is to validate graphene as a brain interface material and to develop devices for both recording neural activity and for brain stimulation. The other partner in this project is the Austrian company Guger Technologies.
July 3, 2014
In recent years, cancer research has been focused on the identification of mutations in genes involved in tumor development. Nevertheless, the molecular pathways that contribute to the progression of the disease remain quite unknown. The journal Nature publishes a paper in which an international team of scientists, led by Nabeel Bardesy, PhD, from the Harvard Medical School, suggests that a mutation in the IDH enzyme (isocitrate dehydrogenase), that occurs in liver progenitor cells, promotes the progression of cholangiocarcinoma, a type of liver cancer. Josep M. Llovet, MD, PhD, ICREA Research Professor at the HCC Translational Research Lab of the Liver Unit at IDIBAPS and Director of Mount Sinai Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York) has collaborated in the study together with Daniela Sia, PhD, and Helena Cornellà, members of the same research group.
Monday, 09/29/2014 · IDIBAPS SEMINAR
Elsie T. Friedman Professor of Pathology Harvard Medical School Director, Center for Excellence in Vascular Biology, Brigham & Women's Hospital
Vascular Endothelium: Nature’s Container for Blood— New Insights into its Pathobiology
- Esteve Auditorium IDIBAPS-CEK Building c. Rosselló 149-153, Barcelona